Literature DB >> 30567985

The Virulence of Different Vaccinia Virus Strains Is Directly Proportional to Their Ability To Downmodulate Specific Cell-Mediated Immune Compartments In Vivo.

Lorena F D de Freitas1, Rafael P Oliveira2, Mariana C G Miranda3, Raíssa P Rocha1, Edel F Barbosa-Stancioli1, Ana Maria C Faria3, Flávio G da Fonseca4.   

Abstract

Vaccinia virus (VACV) is a notorious virus for a number of scientific reasons; however, most of its notoriety comes from the fact that it was used as a vaccine against smallpox, being ultimately responsible for the eradication of that disease. Nonetheless, many different vaccinia virus strains have been obtained over the years; some are suitable to be used as vaccines, whereas others are virulent and unsuitable for this purpose. Interestingly, different vaccinia virus strains elicit different immune responses in vivo, and this is a direct result of the genomic differences among strains. In order to evaluate the net result of virus-encoded immune evasion strategies of vaccinia viruses, we compared antiviral immune responses in mice intranasally infected by the highly attenuated and nonreplicative MVA strain, the attenuated and replicative Lister strain, or the virulent WR strain. Overall, cell responses elicited upon WR infections are downmodulated compared to those elicited by MVA and Lister infections, especially in determined cell compartments such as macrophages/monocytes and CD4+ T cells. CD4+ T cells are not only diminished in WR-infected mice but also less activated, as evaluated by the expression of costimulatory molecules such as CD25, CD212, and CD28 and by the production of cytokines, including tumor necrosis factor alpha (TNF-α), gamma interferon (IFN-γ), interleukin-4 (IL-4), and IL-10. On the other hand, MVA infections are able to induce strong T-cell responses in mice, whereas Lister infections consistently induced responses that were intermediary between those induced by WR and MVA. Together, our results support a model in which the virulence of a VACV strain is proportional to its potential to downmodulate the host's immune responses.IMPORTANCE Vaccinia virus was used as vaccine against smallpox and was instrumental in the successful eradication of that disease. Although smallpox vaccination is no longer in place in the overall population, the use of vaccinia virus in the development of viral vector-based vaccines has become popular. Nonetheless, different vaccinia virus strains are known and induce different immune responses. To look into this, we compared immune responses triggered by mouse infections with the nonreplicative MVA strain, the attenuated Lister strain, or the virulent WR strain. We observed that the WR strain was capable of downmodulating mouse cell responses, whereas the highly attenuated MVA strain induced high levels of cell-mediated immunity. Infections by the intermediately attenuated Lister strain induced cell responses that were intermediary between those induced by WR and MVA. We propose that the virulence of a vaccinia virus strain is directly proportional to its ability to downmodulate specific compartments of antiviral cell responses.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  Lister strain; MVA; Western Reserve strain; modulation of the host immune response; mouse model; vaccinia virus

Mesh:

Substances:

Year:  2019        PMID: 30567985      PMCID: PMC6401461          DOI: 10.1128/JVI.02191-18

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

1.  Growth and maintenance of chick embryo fibroblasts (CEF).

Authors:  Raquel Hernandez; Dennis T Brown
Journal:  Curr Protoc Microbiol       Date:  2010-05

2.  Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara.

Authors:  Eric Sandström; Charlotta Nilsson; Bo Hejdeman; Andreas Bråve; Göran Bratt; Merlin Robb; Josephine Cox; Thomas Vancott; Mary Marovich; Richard Stout; Said Aboud; Muhammad Bakari; Kisali Pallangyo; Karl Ljungberg; Bernard Moss; Patricia Earl; Nelson Michael; Deborah Birx; Fred Mhalu; Britta Wahren; Gunnel Biberfeld
Journal:  J Infect Dis       Date:  2008-11-15       Impact factor: 5.226

3.  Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine.

Authors:  J C Ramírez; M M Gherardi; M Esteban
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

Review 4.  The role of the CD28 receptor during T cell responses to antigen.

Authors:  P S Linsley; J A Ledbetter
Journal:  Annu Rev Immunol       Date:  1993       Impact factor: 28.527

5.  A kinetic analysis of immune mediators in the lungs of mice infected with vaccinia virus and comparison with intradermal infection.

Authors:  Patrick C Reading; Geoffrey L Smith
Journal:  J Gen Virol       Date:  2003-08       Impact factor: 3.891

6.  Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus.

Authors:  Carlos Manuel Corona Gutierrez; Alberto Tinoco; Tania Navarro; Mario López Contreras; Roberto Risco Cortes; Patricia Calzado; Lise Reyes; Roberto Posternak; Gianni Morosoli; Mauro Lara Verde; Ricardo Rosales
Journal:  Hum Gene Ther       Date:  2004-05       Impact factor: 5.695

7.  Nonreplicating vaccinia vector efficiently expresses recombinant genes.

Authors:  G Sutter; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

8.  Differences in time of virus appearance in the blood and virus-specific immune responses in intravenous and intrarectal primary SIVmac251 infection of rhesus macaques; a pilot study.

Authors:  L Stevceva; E Tryniszewska; Z Hel; J Nacsa; B Kelsall; R Washington Parks; G Franchini
Journal:  BMC Infect Dis       Date:  2001-07-27       Impact factor: 3.090

9.  Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers.

Authors:  A Guimarães-Walker; N Mackie; S McCormack; T Hanke; C Schmidt; J Gilmour; B Barin; A McMichael; J Weber; K Legg; A Babiker; P Hayes; F Gotch; C Smith; L Dally; L Dorrell; I Cebere; R Kay; N Winstone; S Moore; N Goonetilleke; P Fast
Journal:  Vaccine       Date:  2008-12-02       Impact factor: 3.641

10.  Cellular and humoral immunity against vaccinia virus infection of mice.

Authors:  Rong Xu; Aaron J Johnson; Denny Liggitt; Michael J Bevan
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

View more
  5 in total

1.  Four Decades of Prophylactic EBV Vaccine Research: A Systematic Review and Historical Perspective.

Authors:  Gabriela M Escalante; Lorraine Z Mutsvunguma; Murali Muniraju; Esther Rodriguez; Javier Gordon Ogembo
Journal:  Front Immunol       Date:  2022-04-14       Impact factor: 8.786

2.  Pseudocowpox virus, a novel vector to enhance the therapeutic efficacy of antitumor vaccination.

Authors:  Rodrigo Nalio Ramos; Caroline Tosch; Fiorella Kotsias; Marie-Christine Claudepierre; Doris Schmitt; Christelle Remy-Ziller; Chantal Hoffmann; Marine Ricordel; Virginie Nourtier; Isabelle Farine; Laurence Laruelle; Julie Hortelano; Clementine Spring-Giusti; Christine Sedlik; Christophe Le Tourneau; Caroline Hoffmann; Nathalie Silvestre; Philippe Erbs; Kaidre Bendjama; Christine Thioudellet; Eric Quemeneur; Eliane Piaggio; Karola Rittner
Journal:  Clin Transl Immunology       Date:  2022-05-08

3.  Enhanced Efficacy of Vaccination With Vaccinia Virus in Old vs. Young Mice.

Authors:  Evgeniya V Shmeleva; Geoffrey L Smith; Brian J Ferguson
Journal:  Front Immunol       Date:  2019-07-31       Impact factor: 7.561

Review 4.  Viral Vector Vaccines against Bluetongue Virus.

Authors:  Luis Jiménez-Cabello; Sergio Utrilla-Trigo; Eva Calvo-Pinilla; Sandra Moreno; Aitor Nogales; Javier Ortego; Alejandro Marín-López
Journal:  Microorganisms       Date:  2020-12-25

5.  Zoonotic vaccinia virus strains belonging to different genetic clades exhibit immunomodulation abilities that are proportional to their virulence.

Authors:  Karine Lima Lourenço; Leandro Andrade Chinália; Lethícia Ribeiro Henriques; Rodrigo Araújo Lima Rodrigues; Flávio Guimarães da Fonseca
Journal:  Virol J       Date:  2021-06-09       Impact factor: 4.099

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.